Antibacterial action of extracellular mammalian group IIA phospholipase A2 against grossly clumped Staphylococcus aureus.
Fibrinogen-dependent interactions of Staphylococcus aureus are believed to contribute to bacterial virulence by promoting bacterial attachment to fibrinogen-coated surfaces and inducing the formation of bacterial clumps that are likely resistant to phagocytosis. Although S. aureus produces several fibrinogen-binding proteins, the cell wall-associated protein clumping factor (encoded by clfA) appears to be most important in bacterial interactions with immobilized or soluble purified fibrinogen. We have compared bacterial clumping in several strains of S. aureus, including isogenic ClfA+ and ClfA- Newman strains, in the presence of purified rabbit fibrinogen, human plasma, and inflammatory fluid and examined the effect of clumping on bacterial sensitivity to mammalian group IIA phospholipase A2 (PLA2). This enzyme is the major extracellular bactericidal agent in inflammatory fluid active against S. aureus. Both ClfA-dependent and ClfA-independent bacterial clumping was observed, depending on the source and fibrinogen content of the biological fluid. In each case, clumping only partially reduced the antibacterial activity of PLA2, suggesting that this extracellular enzyme can substantially penetrate dense bacterial clumps. Bacterial clumps could be dispersed by added proteases, restoring full antibacterial activity to PLA2. Thus, the extracellular mobilization of group IIA PLA2 during inflammation may provide a mechanism by which the host can control the proliferation and survival of S. aureus even after bacterial clumping.
Dominiecki
M E
ME
Department of Microbiology, New York University School of Medicine, New York, New York 10016, USA.
Weiss
J
J
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001422:Bacterial Adhesion / Q000187:drug effects / Q000502:physiology; D001826:Body Fluids / Q000382:microbiology; D004352:Drug Resistance, Microbial; D005340:Fibrinogen / Q000502:physiology; D005341:Fibrinolysin / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007249:Inflammation / Q000201:enzymology; D010741:Phospholipases A / Q000145:classification / Q000494:pharmacology*; D054467:Phospholipases A2; D011817:Rabbits; D013045:Species Specificity; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000472:pathogenicity* / Q000502:physiology; D014774:Virulence / Q000187:drug effects / Q000502:physiology
D000900:Anti-Bacterial Agents; D005340:Fibrinogen; D010741:Phospholipases A; D054467:Phospholipases A2; D005341:Fibrinolysin